Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2000 1
2004 4
2006 3
2008 4
2009 1
2010 5
2011 10
2012 4
2013 4
2014 1
2015 1
2016 1
2017 3
2018 4
2019 2
2020 2
2021 5
2022 3
2023 2
2024 1
2025 5
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk.
Sehayek D, Cole J, Björnson E, Wilkins JT, Mortensen MB, Dufresne L, Pencina KM, Pencina MJ, Thanassoulis G, Sniderman AD. Sehayek D, et al. J Clin Lipidol. 2025 Jul-Aug;19(4):844-859. doi: 10.1016/j.jacl.2025.05.024. Epub 2025 Jun 6. J Clin Lipidol. 2025. PMID: 40681368
BACKGROUND: Conventional statistical approaches are not designed to compare highly correlated variables such as low-density lipoprotein cholesterol (LDL-C), non-high density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (apoB). ...In …
BACKGROUND: Conventional statistical approaches are not designed to compare highly correlated variables such as low-density lipoprotein c …
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, Murphy SA, Goodrich EL, Zhang S, Gaudet D, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano RP, Sabatine MS; Bridge–TIMI 73a Investigators. Bergmark BA, et al. N Engl J Med. 2024 May 16;390(19):1770-1780. doi: 10.1056/NEJMoa2402309. Epub 2024 Apr 7. N Engl J Med. 2024. PMID: 38587249 Clinical Trial.
The 50-mg and 80-mg doses of olezarsen reduced triglyceride levels by 49.3 percentage points and 53.1 percentage points, respectively, as compared with placebo (P<0.001 for both comparisons). As compared with placebo, each dose of olezarsen also significantly reduced th …
The 50-mg and 80-mg doses of olezarsen reduced triglyceride levels by 49.3 percentage points and 53.1 percentage points, respectively, as co …
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.
Navar AM, Mikhailova E, Catapano AL, Banka P, Blom DJ, Cadena A, Kourpanidis S, Lepor NE, Tsukamoto K, Mendizabal G, Nunez J, Zhang W, Zhu P, Zhuo M, Ballantyne CM; CORALreef Lipids Investigators. Navar AM, et al. N Engl J Med. 2026 Feb 5;394(6):529-539. doi: 10.1056/NEJMoa2511002. N Engl J Med. 2026. PMID: 41879224 Clinical Trial.
The primary end point was the mean percent change in LDL cholesterol level from baseline to week 24. Key secondary end points were the mean percent change in LDL cholesterol level at week 52 and the mean percent change in levels of non-high-density lipoprotein (n …
The primary end point was the mean percent change in LDL cholesterol level from baseline to week 24. Key secondary end points were th …
Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes.
Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, Hu FB. Jiang R, et al. Diabetes Care. 2004 Aug;27(8):1991-7. doi: 10.2337/diacare.27.8.1991. Diabetes Care. 2004. PMID: 15277429
Comparisons of nested models indicate that non-HDL cholesterol, but not apoB, adds significantly to the prediction of CVD risk beyond LDL cholesterol. ...CONCLUSIONS: Non-HDL cholesterol and apoB are more poten …
Comparisons of nested models indicate that non-HDL cholesterol, but not apoB, adds significantly to the p …
Non-HDL-cholesterol/apolipoprotein B ratio: a useful distinguishing feature in the screening for type III hyperlipoproteinemia.
Murase T, Okubo M, Takeuchi I. Murase T, et al. J Clin Lipidol. 2010 Mar-Apr;4(2):99-104. doi: 10.1016/j.jacl.2010.01.004. Epub 2010 Feb 1. J Clin Lipidol. 2010. PMID: 21122636
RESULTS: Individual values of serum lipids and apolipoproteins did not distinguish type III HL from the two other types of HL. The non-HDL-C/apoB ratio in type III HL was significantly greater than that in the two comparison groups, with no overlap. CO …
RESULTS: Individual values of serum lipids and apolipoproteins did not distinguish type III HL from the two other types of HL. The non …
Is the superiority of apoB over non-HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables?
Sniderman AD, Islam S, Yusuf S, McQueen MJ. Sniderman AD, et al. J Clin Lipidol. 2013 Nov-Dec;7(6):626-31. doi: 10.1016/j.jacl.2013.08.004. Epub 2013 Aug 31. J Clin Lipidol. 2013. PMID: 24314360
BACKGROUND: Patients with increased numbers of cholesterol-depleted apolipoprotein B (apoB) particles frequently have multiple other abnormalities, which might confound the comparison of apoB and non-high-density-lipoprotein-cholesterol (non …
BACKGROUND: Patients with increased numbers of cholesterol-depleted apolipoprotein B (apoB) particles frequently have multiple …
A Comparison of Lipids and apoB in Asian Indians and Americans.
Singh K, Thanassoulis G, Dufresne L, Nguyen A, Gupta R, Narayan KV, Tandon N, Sniderman A, Prabhakaran D. Singh K, et al. Glob Heart. 2021 Jan 20;16(1):7. doi: 10.5334/gh.882. Glob Heart. 2021. PMID: 33598387 Free PMC article.
However, apoB was significantly higher in Asian Indians than Americans. The LDL-C/apoB ratio and the non-HDL-C/apoB ratio were both significantly lower in Asian Indians than Americans. ...ApoB, however, integrates and extends the informat …
However, apoB was significantly higher in Asian Indians than Americans. The LDL-C/apoB ratio and the non-HDL-C/ …
Targets for LDL-lowering therapy.
Sniderman A. Sniderman A. Curr Opin Lipidol. 2009 Aug;20(4):282-7. doi: 10.1097/MOL.0b013e32832ca1d6. Curr Opin Lipidol. 2009. PMID: 19474729 Review.
PURPOSE OF REVIEW: To compare non-HDL-cholesterol (non-HDL-C) and apolipoprotein B (apoB) as targets for LDL-lowering therapy. ...It is also necessary to compare markers for how well they identify residual risk, and, in this regard, ap …
PURPOSE OF REVIEW: To compare non-HDL-cholesterol (non-HDL-C) and apolipoprotein B (apoB) as targe …
A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.
Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. Sniderman AD, et al. Circ Cardiovasc Qual Outcomes. 2011 May;4(3):337-45. doi: 10.1161/CIRCOUTCOMES.110.959247. Epub 2011 Apr 12. Circ Cardiovasc Qual Outcomes. 2011. PMID: 21487090
Whether analyzed individually or in head-to-head comparisons, apoB was the most potent marker of cardiovascular risk (RRR, 1.43; 95% CI, 1.35 to 1.51), LDL-C was the least (RRR, 1.25; 95% CI, 1.18 to 1.33), and non-HDL-C was intermediate (RRR, 1.34; 95 …
Whether analyzed individually or in head-to-head comparisons, apoB was the most potent marker of cardiovascular risk (RRR, 1.4 …
Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials.
Robinson JG, Wang S, Jacobson TA. Robinson JG, et al. Am J Cardiol. 2012 Nov 15;110(10):1468-76. doi: 10.1016/j.amjcard.2012.07.007. Epub 2012 Aug 17. Am J Cardiol. 2012. PMID: 22906895 Review.
In the 12 statin trials, apoB and non-HDL cholesterol decreases similarly predicted cardiovascular disease risk; apoB improved coronary heart disease prediction when added to non-HDL cholesterol/LDL cholesterol decrea …
In the 12 statin trials, apoB and non-HDL cholesterol decreases similarly predicted cardiovascular disease risk; …
60 results